Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (June 2022)

39 slides from Zynerba Pharmaceuticals's investor presentation, Jun 22, 2022

  1. Slide 1: Next-Generation Transdermal Cannabinoid Therapeutics

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next-Generation Transdermal Cannabinoid Therapeutics June 2022

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other things relate to the future operations, opportunities or financial performance of Zynerba ph

  3. Slide 3: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  4. Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company

    An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation-enhanced Patent-protected through 2038 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical prog

  5. Slide 5: Benefits of Our Approach to Cannabidiol

    Benefits of Our Approach to Cannabidiol June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISP

  6. Slide 6: Clinical Development Programs

    Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q Autism Spectrum Disorder ASD

  7. Slide 7: Overlap of Symptoms Across Conditions

    Overlap of Symptoms Across Conditions June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 7 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q ASD

  8. Slide 8: Focused Clinical Pipeline

    Fragile X Syndrome (FXS) Focused Clinical Pipeline June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Autism Spectrum Disorder (ASD) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU

  9. Slide 9: Well-Tolerated Safety Profile

    • Zygel safety database across all clinical studies includes data from over 900 volunteers and patients • Majority of treatment-emergent AEs (TEAE) were mild or moderate • Most common Zygel-related TEAE are application site events, the majority of which were mild and transient • No clinically signif

  10. Slide 10: Fragile X Syndrome

    [ Nap Fragile X Syndrome Fin a

  11. Slide 11: What is Fragile X Syndrome (FXS)

    ~78K U.S. PATIENTS What is Fragile X Syndrome (FXS) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 11 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation •

  12. Slide 12: Poised for Success in FXS

    Poised for Success in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylati

  13. Slide 13: Role of FMR1 Methylation in FXS

    Role of FMR1 Methylation in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gen

  14. Slide 14: CONNECT-FX Trial Key Learning: Complete Methylation Results

    CONNECT-FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CH

  15. Slide 15: Change in ABC-CFXS Social Avoidance

    Change in ABC-CFXS Social Avoidance June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 Clinically Meaningful Changea Achieved and Maintained in Patients with Complete Methylation of FMR1 Geneb 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Cum

  16. Slide 16: Design Optimized from CONNECT-FX Trial

    Design Optimized from CONNECT-FX Trial June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 16 More patient and family friendly Extending trial to 18-weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy requi

  17. Slide 17: Confirmatory Pivotal Trial Design

    Confirmatory Pivotal Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 Double-Blind, Placebo-Controlled Study: Initiated 18 weeks 3 to 17 years old Moderate-to-Severe FXS Zygel (n~100; 80*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>50kg) (we

  18. Slide 18: Trial Objectives

    Trial Objectives June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC-CF

  19. Slide 19: Next Steps in FXS

    Next Steps in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 Continued RECONNECT pivotal trial enrollment Topline results expected in 2H 2023

  20. Slide 20: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org. Eliza, living with 22q11.2 deletion syndrome

  21. Slide 21: What is 22q11.2 Deletion Syndrome (22q)?

    What is 22q11.2 Deletion Syndrome (22q)? June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 21 • Rare disorder and second most common genetic disorder, behind Down syndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically co

  22. Slide 22: Rationale for Zygel in 22q

    U.S. ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction pr

  23. Slide 23: INSPIRE Phase 2 Trial Design

    INSPIRE Phase 2 Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 Period 1: Completed 14 weeks 4 to 15 years old With 22q11.2 Deletion Syndrome Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight-based dose) Period 2: Ongoing 24 weeks Efficacy

  24. Slide 24: INSPIRE Trial Results Summary

    • Statistically significant improvements at 14 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC-C) • Pediatric

  25. Slide 25: ADAMS and ABC-C Results

    ADAMS and ABC-C Results June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 25 ABC -C Subscale Baseline Week 14 Change from Baseline Mean % Improvement p Value Median % Improvement Social Withdrawal 14.4 7.9 -6.4 27.6% 0.0110 46.4% Inappropriate Speech 4.2 2.4 -1.8 18.3% 0.

  26. Slide 26: Next Steps in 22q

    Next Steps in 22q June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 26 Discuss regulatory pathway with FDA Initiate Phase 3 program after FDA discussions and RECONNECT top line results

  27. Slide 27: Autism Spectrum Disorder

    Autism Spectrum Disorder

  28. Slide 28: Rationale for Zygel in Autism Spectrum Disorder (ASD)

    Rationale for Zygel in Autism Spectrum Disorder (ASD) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 28 • Results from FXS trials suggested spectrum of activity against behaviors also seen in ASD: irritability, social avoidance and anxiety • Studies suggested ASD is li

  29. Slide 29: BRIGHT Open-label Phase 2 Trial Design

    BRIGHT Open-label Phase 2 Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 29 Period 1 14 weeks 3 to 16 years old Moderate-to-Severe ASD Zygel (n = 37) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight-based dose) Period 2 24 weeks 18 Patients with ≥ 35% imp

  30. Slide 30: BRIGHT Phase 2 Trial Results: Period 1

    BRIGHT Phase 2 Trial Results: Period 1 Statistically Significant Results at Week 14 Compared to Baseline (Completers in Efficacy Population n=28†) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 30 † n=26 for ABC-C inappropriate speech; *Statistically significant; Full

  31. Slide 31: BRIGHT Period 2 Results: Improvements Sustained Through Week 38

    50% (P<0.0001) 61% (P<0.0001) 60% (P<0.0001) 53% (P<0.0001) 56% (P<0.0001) 0 5 10 15 20 25 30 35 40 Irritability Inappropriate Speech Stereotypy Social Withdrawal Hyperactivity ABC -C Subscale Score Mean Scores Baseline Week 14 Week 38 BRIGHT Period 2 Results: Statistically Significant Improvements

  32. Slide 32: Next Steps in ASD

    Next Steps in ASD June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 32 Submit Investigational New Drug (IND) application specific to ASD with finalized clinical protocol ASD is now third in priority and initiation of phase 3 program is deferred at this time

  33. Slide 33: Positioned for Success

    Positioned for Success

  34. Slide 34: Leadership

    Leadership June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 34 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resour

  35. Slide 35: Financial Strength

    Financial Strength June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 35 CASH AND CASH EQUIVALENTS $69.7M as of March 31, 2022; expected to be sufficient to fund operations and capital requirements to the end of 2023/early 2024 BALANCE SHEET CLEAN No debt, 43.6M shares out

  36. Slide 36: A Year of Clinical Progress Ahead

    A Year of Clinical Progress Ahead June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 36 Fragile X Syndrome (FXS) Autism Spectrum Disorder (ASD) 22q Deletion Syndrome (22q) U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. Orphan Drug designation

  37. Slide 37: Zynerba Vision for Future Growth

    • Launch Zygel for FXS into a $1.9B+ U.S. market opportunity • Establish a fully integrated organization with U.S. commercial presence • Preparing for EU approval in FXS • Advance 22q and ASD Ph3 programs towards completion • Leaders in transdermal cannabidiol delivery • Late-stage clinical company

  38. Slide 38: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  39. Slide 39: Thank you!

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!

Zynerba Pharmaceuticals — Investor Presentation (June 2022) on 6ix